Original
Efectividad y seguridad en nuestro entorno de adalimumab como tratamiento anti-TNF de primera linea en niños con enfermedad de Crohn
A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for pediatric Crohn's disease
Víctor Manuel Navas-Lópeza,b,
, Gemma Pujol Muncunillc, Enrique Llerenac, María Navalón Rubiod, David Gil-Ortegad, Vicente Varea-Calderónc, Carlos Sierra Salinasa,b, Javier Martin-de-Carpic
a Sección de Gastroenterología y Nutrición Infantil, Hospital Materno Infantil, Málaga, España
b Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España
c Unidad para el Cuidado Integral de la Enfermedad Inflamatoria Intestinal Pediátrica, Sección de Gastroenterología, Hepatología y Nutrición Pediátrica, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, España
d Unidad de Gastroenterología y Nutrición Pediátrica, Hospital Virgen de la Arrixaca, Murcia, España
Leído
11708
Vecesse ha leído el artículo
3274
Total PDF
8434
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 20 | 2 | 22 |
| 2025 5 | 116 | 30 | 146 |
| 2025 4 | 98 | 22 | 120 |
| 2025 3 | 117 | 26 | 143 |
| 2025 2 | 105 | 22 | 127 |
| 2025 1 | 105 | 25 | 130 |
| 2024 12 | 91 | 36 | 127 |
| 2024 11 | 112 | 62 | 174 |
| 2024 10 | 66 | 30 | 96 |
| 2024 9 | 88 | 38 | 126 |
| 2024 8 | 88 | 53 | 141 |
| 2024 7 | 81 | 24 | 105 |
| 2024 6 | 78 | 40 | 118 |
| 2024 5 | 76 | 26 | 102 |
| 2024 4 | 92 | 41 | 133 |
| 2024 3 | 56 | 39 | 95 |
| 2024 2 | 90 | 32 | 122 |
| 2024 1 | 50 | 36 | 86 |
| 2023 12 | 95 | 23 | 118 |
| 2023 11 | 69 | 31 | 100 |
| 2023 10 | 77 | 27 | 104 |
| 2023 9 | 94 | 30 | 124 |
| 2023 8 | 97 | 18 | 115 |
| 2023 7 | 98 | 29 | 127 |
| 2023 6 | 102 | 33 | 135 |
| 2023 5 | 95 | 18 | 113 |
| 2023 4 | 89 | 20 | 109 |
| 2023 3 | 115 | 31 | 146 |
| 2023 2 | 87 | 36 | 123 |
| 2022 1 | 93 | 18 | 111 |
| 2022 12 | 90 | 30 | 120 |
| 2022 11 | 121 | 40 | 161 |
| 2022 10 | 108 | 52 | 160 |
| 2022 9 | 73 | 31 | 104 |
| 2022 8 | 98 | 59 | 157 |
| 2022 7 | 94 | 57 | 151 |
| 2022 6 | 93 | 45 | 138 |
| 2022 5 | 103 | 31 | 134 |
| 2022 4 | 156 | 41 | 197 |
| 2022 3 | 186 | 61 | 247 |
| 2022 2 | 179 | 37 | 216 |
| 2021 1 | 193 | 47 | 240 |
| 2021 12 | 95 | 45 | 140 |
| 2021 11 | 113 | 57 | 170 |
| 2021 10 | 132 | 86 | 218 |
| 2021 9 | 75 | 44 | 119 |
| 2021 8 | 94 | 38 | 132 |
| 2021 7 | 75 | 36 | 111 |
| 2021 6 | 90 | 44 | 134 |
| 2021 5 | 88 | 63 | 151 |
| 2021 4 | 162 | 115 | 277 |
| 2021 3 | 100 | 44 | 144 |
| 2021 2 | 91 | 28 | 119 |
| 2020 1 | 81 | 29 | 110 |
| 2020 12 | 129 | 38 | 167 |
| 2020 11 | 58 | 34 | 92 |
| 2020 10 | 85 | 36 | 121 |
| 2020 9 | 88 | 37 | 125 |
| 2020 8 | 64 | 18 | 82 |
| 2020 7 | 118 | 38 | 156 |
| 2020 6 | 116 | 23 | 139 |
| 2020 5 | 78 | 27 | 105 |
| 2020 4 | 64 | 41 | 105 |
| 2020 3 | 87 | 33 | 120 |
| 2020 2 | 78 | 36 | 114 |
| 2020 1 | 86 | 38 | 124 |
| 2019 12 | 112 | 31 | 143 |
| 2019 11 | 54 | 15 | 69 |
| 2019 10 | 72 | 22 | 94 |
| 2019 9 | 50 | 24 | 74 |
| 2019 8 | 123 | 29 | 152 |
| 2019 7 | 59 | 30 | 89 |
| 2019 6 | 73 | 24 | 97 |
| 2019 5 | 150 | 25 | 175 |
| 2019 4 | 121 | 36 | 157 |
| 2019 3 | 87 | 32 | 119 |
| 2019 2 | 143 | 16 | 159 |
| 2019 1 | 70 | 40 | 110 |
| 2018 12 | 96 | 40 | 136 |
| 2018 11 | 176 | 50 | 226 |
| 2018 10 | 184 | 34 | 218 |
| 2018 9 | 97 | 28 | 125 |
| 2018 8 | 1 | 0 | 1 |
| 2018 7 | 7 | 0 | 7 |
| 2018 6 | 9 | 0 | 9 |
| 2018 5 | 31 | 0 | 31 |
| 2018 4 | 180 | 1 | 181 |
| 2018 3 | 138 | 3 | 141 |
| 2018 2 | 20 | 7 | 27 |
| 2018 1 | 0 | 12 | 12 |
| 2017 12 | 0 | 10 | 10 |
| 2017 11 | 0 | 21 | 21 |
| 2017 10 | 0 | 24 | 24 |
| 2017 9 | 0 | 26 | 26 |
| 2017 8 | 0 | 17 | 17 |
| 2017 7 | 0 | 9 | 9 |
| 2017 6 | 0 | 18 | 18 |
| 2017 5 | 0 | 65 | 65 |
| 2017 4 | 0 | 128 | 128 |
Mostrar todo
